Results 21 to 30 of about 2,403,288 (173)

“Chronic myelogenous leukemia in primary blast crisis” rather than “de novo BCR‐ABL1‐positive acute myeloid leukemia”

open access: yesClinical Case Reports, 2017
Key Clinical Message Differentiating chronic myelogenous leukemia in primary blast crisis (CML‐BC) from de novo BCR‐ABL1‐positive acute myeloid leukemia (AML) is a diagnostic challenge with therapeutic consequences.
Cedric Pastoret, Roch Houot
doaj   +1 more source

Eradication of chronic myeloid leukemia stem cells: a novel mathematical model predicts no therapeutic benefit of adding G-CSF to imatinib [PDF]

open access: yes, 2009
Imatinib mesylate induces complete cytogenetic responses in patients with chronic myeloid leukemia (CML), yet many patients have detectable BCR-ABL transcripts in peripheral blood even after prolonged therapy.
Holyoake, T.   +14 more
core   +2 more sources

Therapeutic choices in patients with Ph-Positive chronic myelogenous leukemia in Mexico in the era of tyrosine kinase inhibitors: stem cell transplantation or tyrosine kinase inhibitors? Fifteen years later

open access: yesRevista de Investigación Clínica
Background: Chronic myelogenous leukemia is a neoplastic proliferation of the granulocytic series. In Mexico, chronic myelogenous leukemia accounts for approximately 10% of all leukemias.
Max Robles-Nasta   +8 more
doaj   +1 more source

Permanent Sensorineural Deafness in a Patient with Chronic Myelogenous Leukemia Secondary to Intracranial Hemorrhage

open access: yesCase Reports in Hematology, 2013
A 52-year-old male presented with tinnitus and fullness in left ear for one day. Workup revealed a white blood cell count of 685×103/μL with marked increase in granulocyte series and myeloid precursors on peripheral smear.
Sakshi Kapur   +3 more
doaj   +1 more source

New Bcr-Abl-independent mechanisms of resistance to imatinib treatment in chronic myelogenous leukaemia patients [PDF]

open access: yes, 2008
Although rare in chronic phase myeloid leukemia (CML), primary or acquired resistance to the treatment with tyrosine kinase inhibitors (TKI) may be observed in the advanced phases of disease.
Esposito, Nicola
core   +1 more source

Erythroid blast crisis in chronic myelogenous leukemia: Case report and review of literature

open access: yesLeukemia Research Reports, 2016
Chronic myelogenous leukemia (CML) is a myeloproliferative disorder where over a period of time 15–20% of patients show blastic transformation with majority transforming into acute myeloid leukemia, most of which are of granulocytic lineage.
Rochelle Nagales Nagamos   +2 more
doaj   +1 more source

A case report of bosutinib-induced interstitial granulomatous drug reaction in a patient with chronic myelogenous leukemia: a case report

open access: yesSAGE Open Medical Case Reports, 2018
Bosutinib is a BCR-ABL tyrosine kinase inhibitor approved for the treatment of Philadelphia chromosome–positive chronic myelogenous leukemia. We report a case of bosutinib-induced interstitial granulomatous drug reaction in a 50-year-old Caucasian female
Alexander B Aria   +2 more
doaj   +1 more source

Human immunodeficiency virus Infection in a patient of chronic myelogenous leukemia

open access: yesIndian Journal of Medical and Paediatric Oncology, 2013
Association of Cancer and HIV infection is seen in practice. Commonly observed cancer in HIV infected patients are Non-Hodgkin′s Lymphoma, cervical cancer and Kaposi Sarcoma, Coexistent Chronic Myelogenous Leukemia (CML) and HIV infection are rare.
Vijay B Tuljapurkar, Uday A Phatak
doaj   +1 more source

Targeting USP47 overcomes tyrosine kinase inhibitor resistance and eradicates leukemia stem/progenitor cells in chronic myelogenous leukemia

open access: yesNature Communications, 2021
Resistance to tyrosine kinase inhibitors (TKI) is a limitation to their use in treating chronic myelogenous leukemia (CML). Here, the authors show that targeting the ubiquitin peptidase USP47 overcomes TKI resistance and eliminates leukaemia stem ...
Hu Lei   +21 more
doaj   +1 more source

Direct evidence that leukemic cells present HLA-associated immunogenic peptides derived from the BCR-ABL b3a2 fusion protein [PDF]

open access: yes, 2001
The BCR-ABL oncogene is central in the pathogenesis of chronic myeloid leukemia (CML). Here, tandem nanospray mass spectrometry was used to demonstrate cell surface HLA- associated expression of the BCR-ABL peptide KQSSKALQR on class I-negative CIVIL ...
Lill, JR   +14 more
core   +1 more source

Home - About - Disclaimer - Privacy